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Abstract
Background: Globally, cancer is one of the leading causes of mortality. High treatment cost, partly owing to higher
prices of anti-cancer drugs, presents a significant burden on patients and healthcare systems. The aim of the
present study was to survey and compare retail prices of anti-cancer drugs between high, middle and low income
countries in the South-East Asia, Western Pacific and Eastern Mediterranean regions.
Methods: Cross-sectional survey design was used for the present study. Pricing data from ten counties including
one from South-East Asia, two from Western Pacific and seven from Eastern Mediterranean regions were used in this
study. Purchasing power parity (PPP)-adjusted mean unit prices for 26 anti-cancer drug presentations (similar
pharmaceutical form, strength, and pack size) were used to compare prices of anti-cancer drugs across three regions. A
structured form was used to extract relevant data. Data were entered and analysed using Microsoft Excel®.
Results: Overall, Taiwan had the lowest mean unit prices while Oman had the highest prices. Six (23.1%) and nine (34.
6%) drug presentations had a mean unit price below US$100 and between US$100 and US$500 respectively. Eight
drug presentations (30.7%) had a mean unit price of more than US$1000 including cabazitaxel with a mean unit price
of $17,304.9/vial. There was a direct relationship between income category of the countries and their mean unit price;
low-income countries had lower mean unit prices. The average PPP-adjusted unit prices for countries based on their
income level were as follows: low middle-income countries (LMICs): US$814.07; high middle income countries (HMICs):
US$1150.63; and high income countries (HICs): US$1148.19.
Conclusions: There is a great variation in pricing of anticancer drugs in selected countires and within their respective
regions. These findings will allow policy makers to compare prices of anti-cancer agents with neighbouring countries
and develop policies to ensure accessibility and affordability of anti-cancer drugs.
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Background
Earlier diagnosis and longer treatment durations con-
tribute to rising expenditure on medicine for cancer
care. Access to cancer treatment can be a challenge,
since it is significantly affected by cost, particularly in
low and middle-income countries. According to the
Global Oncology Trend Report [1], global spending on
cancer medications rose from $75 billion in 2010 to
$100 billion in 2014, 10.3% rise in spending. Medication
cost is a strong predictor of adherence [2, 3] with the
risk of cost-related non-adherence being higher for those
with lower income and higher out-of-pocket (OOP) drug
spending [3].These growing costs inevitably provoke
concern regarding the financial burden experienced by
cancer patients [1]. This concern is even more promin-
ent in Asia because it is home to half of the world’s ex-
tremely poor population [4].
Asia accounts for 60% of the world population and
50% of the global burden of cancer [4]. The projected in-
crease in cancer incidence is predicted to be most* Correspondence: muhammad.hadi@dmu.ac.uk
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significant in low and medium—income countries in
Asia [4, 5].
Asia is very heterogeneous in terms of healthcare sys-
tems. With the exception of a few high-income countries
such as Israel, Kuwait, Qatar, the Republic of Korea,
Singapore, and the United Arab Emirates who enjoy
well-developed health services, the vast majority of the
Asian people face a substantial cancer burden because
cancer care remains a low priority in healthcare planning
and expenditure [4]. In these countries, over 60% of the
total healthcare expenditure comes from private re-
sources, of which more than 80% is direct out of pocket
payments, with catastrophic results for most families in
these countries [4]. Similarly, in the Middle East, spend-
ing per capita on cancer drugs is considerably less than
in Europe or the US [6]. The cancer drug expenditure as
a percentage of total drug expenditure is very low in
Middle Eastern countries [6].
In this study, we aim to build on the existing body of
work by providing comparable cancer drug retail prices
across countries in the South-East Asian [SEA], Western
Pacific (WP) and Eastern Mediterranean (EM) regions.
A review based approach utilising selective content ana-
lysis has been adopted to achieve the objective of this
paper. A previous study on comparing cancer drug
prices focused on 18 high-income countries, member of
economic co-operation and development (OECD) coun-
tries, in Europe and Oceania [7]. To our knowledge, this
is one of the very first initiatives taken to compare the
retail price of cancer drugs across countries in the
South-East Asia, Western Pacific and Eastern Mediterra-
nean regions. By analysing and comparing the unit
prices across Asian countries with differing gross na-
tional income (GNI) per capita, we are hoping to assist
in improving procurements, price negotiations, and loca-
tion of new supply sources, and ultimately to create an
opportunity for patients in Asia to gain access to more
affordable cancer treatments.
Methods
Country selection
The following criteria were adopted for the inclusion of
countries:
 Geographically located in the South-East Asian,
Western Pacific or Eastern Mediterranean regions
 Availability of drug pricing data published by
respective pricing/health authorities.
Based on the inclusion criteria, Thailand was the only eli-
gible country from South-East Asia, Malaysia and Taiwan
were included from the Western Pacific, and Oman,
Pakistan, the United Arab Emirates, Lebanon, Egypt, Saudi
Arabia and Bahrain from the Eastern Mediterranean
region. Countries in the Asia Pacific [Australia and New
Zealand] were excluded from this study, despite being part
of the Western Pacific region, as they had already been
covered in previous studies [7]. The included countries
were classified into Low income [LIC], low middle income
[LMIC], high middle income [HMIC] and high income
[HIC] countries based on their GNI per capita, using the
cut off points provided by the world bank website [8]. The
United Nation’s 3-letter standard abbreviations [ISO
ALPHA-3 code] were used to represent country names in
Tables 1, 2 and 3. [9]
Data sources
The price of the cancer drugs in the ten included coun-
tries was retrieved from official pricing authorities or the
respective Ministry of Health or equivalent websites
[Table 1]. The authors ensured that the prices were re-
trieved from the most recent price lists published by the
respective countries. The prices retrieved for Bahrain,
Lebanon, Oman and Taiwan were published in 2016 and
the prices for the remaining countries were published in
2015. However, the exact publication date of the pricing
data was unclear.
The GNI per capita [USD] of nine of the ten included
countries was retrieved from the World Bank website.
For Taiwan, however, the data had to be retrieved
from Taiwan’s national statistics bureau [10] since the
country is not a member of United Nations and was
not listed on the World Bank website. The respective
GNI per capita and country classifications are shown
in Additional file 1: Table S2.
Medicine selection
A cross–country comparison of 31 selected samples of
cancer drugs was made by Vogler et al. [7] whereby the
selection of drugs was also dependent on the data avail-
ability and availability of comparable products in the
market in at least ten countries. In this study, the same
31 drug presentations were chosen initially as a guide.
The inclusion criterion for selecting a drug presenta-
tion was the availability its pricing data in at least four
out of the ten countries.
Data analysis
The price data were reviewed by the six co-authors. As the
unit of measurement, we selected retail price per unit [i.e.
per tablet/capsule or per vial]. Retail prices were chosen in
this study because they represent the patients’ actual out of
pocket expenditure. Another advantage of using retail
prices is that they include all the add-ons such as taxes,
distribution and pharmacist fees; these add-ons sometimes
lead to the final price costing more than double the actual
cost of the drug [11, 12]. The other reason for the use
of retail prices was that ex-factory prices are hard to
Salmasi et al. BMC Cancer  (2017) 17:903 Page 2 of 11
measure accurately, especially in countries that have
no publicly funded drug coverage. [12]
Prices were only included if they referred to the same
presentation in terms of pack size, strength and pharma-
ceutical form. Pricing data were originally extracted and
presented in national currencies but later converted to
USD using purchasing power parity (PPP) to allow fair
comparison between different countries. Microsoft Excel
was used for PPP-related calculations. Purchasing power
parity rates were retrieved from the World Bank website
[8]. The purchasing power parity conversion rates used
are presented in Additional file 1: Table S1. The mean
unit prices were calculated for each drug presentation as
well as for each country. The high/low ratio for each
presentation was calculated by dividing the highest unit
price of the presentation by the lowest unit price of the
same presentation to analyze the inter-country variability
of the price for every presentation. A high/low ratio of
10 implies that the highest unit price is ten times more
expensive than the lowest unit price. All calculations
were performed in Microsoft Excel. All statistical ana-
lyses were descriptive.
In order to present the price comparison more effect-
ively, the results have been arranged into the World Bank
categories and comparisons are made accordingly. Of the
ten included countries, one country [Pakistan] is classified
as a low-income country, one [Egypt] as middle-income,
three [Thailand, Malaysia and Lebanon] as higher-middle
income, and five [the United Arab Emirates, Bahrain, Saudi
Arabia, Oman and Taiwan] as high-income countries.
Results
Upon applying the selection criteria for presentations, the
following presentations that were originally in Vogler et
al.’s study [7] were excluded from this study due to a lack
of pricing information for at least four countries: benda-
mustine [HCl], bevacizumab [16 ml vial], clofarabine, eri-
bulin mesylate, lenalinomide, nelarabine, ofatumumab,
plerixafor, sorafenib [112-tablet pack], temsirolimus and
vemurafenib. On the other hand, five additional presenta-
tions for which price data was available in the included
regions were added to the list: nilotinib 200 mg, suni-
tinib 12·5 and 25 mg, trastuzumab 440 mg, and sorafenib
[60-tablet pack].
We were unable to find pricing data on sorafenib [the
112-tablet box] so we replaced it with the 60-tablet box
for which pricing data was available. Moreover, we found
adequate data for trastuzumab 440 mg in the regions of
interest, therefore we added it to the list despite already
having a presentation for this drug [trastuzumab 150 mg].
Although it was expected that the two would follow the
same pattern, the pricing data was included to provide
more information for the readers. The same was true for
sunitinib [12·5 mg, 25 mg and 50 mg] and nilotinib
[150 mg and 200 mg].
The final number of included presentations was 26.
Table 2 provides an overview of the selected drugs with
regards to their FDA-approved indications, selected pres-
entation and country coverage. We only compared prices
for the originator drugs because pricing policies for origin-
ator drugs differ substantially from generic vials.
Table 1 Data sources used in this study
Countries Data sources Specification
UAE United Arab Emirates Ministry of Health Drug Department
URL:http://www.cpd-pharma.ae/downloads/Price-List-February/MoH-Price-List-
as-on-07-Feb-2015.pdf
The data was retrieved from MOH, drug department.
The Document includes both imported and generic
drugs and it was last updated on Feb 2015.
Bahrain National Health Regulatory Authority
URL: http://www.nhra.bh/SitePages/View.aspx?PageId=42
The Drug Price List includes both innovator and generic
medicines prices. Last updated on 14 March 2016
Taiwan National Health Insurance Administration, Ministry of Health and Welfare
URL: http://www.nhi.gov.tw/query/Query1.aspx
The data was retrieved from Ministry of Health and
Welfare of Taiwan. The Document includes both imported
and generic drugs and it was last updated on June 2016.
Thailand Drug And Medical Supply Information Center, Ministry of Public Health
URL: http://dmsic.moph.go.th/dmsic/index.php?p=1&type=3&s=3&id=
p_drug_normal_en&lang=en
The Drug Reference Price list provides the medical
supplies prices for commercial sector. Last updated
on March 2015.
Malaysia Pharmaceutical Services Division, Ministry of Health
URL: http://www.pharmacy.gov.my/v2/en/apps/drug-price
The Consumer Price Guide provides retail price list to
serve as guidance to patients when purchasing medicines.
Lebanon Ministry of Public Health
URL: http://www.moph.gov.lb/Drugs/Pages/Drugs.aspx
The data was retrieved from the MoPH Drugs Public
Price List. Last updated on 16 February 2016
Oman Ministry of Health https://www.moh.gov.om/en/web/dgpadc/resources The data was retrieved from the Ministry of Health,
Sultanate of Oman website from the list of registered
drugs. Last updated on 17–05-2016.
Pakistan PharmaGuide book, Pakistan edition, 24th edition. The pricing data was retrieved PharmaGuide
Book. This handbook is published annually providing
essential prescribing and trade information. The pricing
data was retrieved from the latest edition (24th) published
on March 2016.
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Table 2 Background information about drugs included in the analysisa
Generic drug
name
Product name FDA approved indications Selected presentation Country coverage Unit price is
price of:# Missing data
Abiraterone
acetate
Zytiga Metastatic castration-resistant
prostate cancer
120 tablets 250 mg 7 PAK, MYS, LBN 1 Tab
Bevacizumab Avastin NSCLC
Metastatic Colorectal cancer,
Glioblastoma
Metastatic Renal cell carcinoma
Metastatic Her2 negative breast
cancer
Metastatic cervical cancer.
One 4 ml vial containing
25 mg/mL concentrate for
solution for infusion.
6 MYS, SAU, OMN, LBN 4 ml vial
Bortemozib Velcade One vial containing 3·5 mg
powder for solution for injection.
7 EGY, PAK, SAU 1 vial
Cabazitaxel JEVTANA® Metastatic hormone refractory
prostate cancer
One vial containing 60 mg
concentrate and solvent for
solution for infusion.
4 EGY, PAK,THA, SAU,
BHR,TWN,
1 vial
Cetuximab Erbitux K-ras wild-type, EGFR-expressing
metastatic colorectal cancer.
Recurrent/metastatic head and
neck cancer
One vial containing 5 mg/mL
solution for infusion.
4 ARE, EGY, PAK,
SAU,OMN, BHR
1 vial
Denosumab Prolia Unresectable giant cell tumor of
bone in adults and skeletally
mature adolescents
One pre-filled syringe containing
60 mg solution for injection
6 PAK, MYS, SAU, BHR One pre-filled
syringe
Erlotinib HCl Tarceva Non-small cell lung cancer.
Pancreatic cancer.
30 film-coated tablets 150 mg 7 MYS, SAU, LBN 1 film-coated
Tab
Everolimus Afinitor Subependymal giant cell
astrocytoma.
HER2-negative breast cancer.
Progressive neuroendocrine
Tumors of Pancreatic origin.
Advanced renal cell carcinoma.
30 tablets 10 mg 8 PAK, MYS, 1 Tab
Gefitinib Iressa Non-small cell lung cancer 30 film-coated tablets 250 mg 7 EGY, SAU,PAK 1 film coated
Tab
Gemcitabine Gemita (Atco) Ovarian cancer
Breast cancer.
NSLCLC
Pancreatic cancer
1 vial containing 1 g powder
for solution for infusion.
9 SAU 1 vial
Imatinib
Mesylate
Glivec (Novertis) Dermatofibrosarcoma protuberans.
Gastrointestinal stromal tumor.
Myelodysplastic/myeloproliferative
neoplasms.
Systemic mastocytosis.
Chronic Eosinophilic leukemia.
Chronic Myelogenous Leukemia
60 film-coated tablets 100 mg 9 BHR 1 film coated
Tab
Interferon
Alpha - 2B
Interon A
(Schering Plough
AIDS related Kaposi Sarcoma.
Hairy cell leukemia.
Melanoma.
NHL
One multi-dose pen containing
3 million IU/0·5 mL solution for
injection.
6 THA, EGY, MYS,OMN One multi-
dose pen
Lapatinib
ditosylate
Tykerb FC HER2 positive breast cancer, 70 film-coated tablets 250 mg 7 MYS, BHR, TWN 1 film coated
Tab
Nilotinib Tasigna CML 112 capsules 150 mg 8 PAK, MYS 1 Cap
112 capsules 200 mg 6 THA,LBN, OMN, BHR 1 Cap
Paclitaxel
Albumin
Intaxel 30 mg/
5 ml inj
NSCLC
Breast cancer pancreatic cancer
One vial containing 5 mg/ml
powder for suspension for infusion.
6 ARE, EGY, SAU, BHR 1 Vial
Panitumumab Vectibix 400 mg/
20 ml IV
Colorectal Cancer One vial containing 20 mg/ml
concentrate for solution for infusion
6 THA, PAK, MYS, TWN 1 Vial
Pazopanib votrient 30 film-coated tablets 200 mg 8 PAK, MYS 1 film coated
Tab
Alimta (Eli Lilly) non-squamous NSCLC 9 OMN 1 Vial
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Unit price
Table 3 represents prices per package as well as the cal-
culated unit prices in USD using PPP. Upon estimating
the PPP, cabazitaxel was the most expensive drug with a
unit price of $17,304·9/vial [in Oman]. Nilotinib 150 mg
had the lowest unit price in USD [$19·22/tab in Egypt].
The PPP adjusted USD unit prices for each medication
are represented in Fig. 1. The different unit prices are
connected to illustrate variations between countries. To
ensure that the variations among prices is easy to dis-
cern for both low price and high price medications,
the two have been presented in two different figures.
Figure 1a represents cancer drugs with unit price be-
tween $0–1000, while Fig. 1b represents cancer drugs
with unit prices between $1000–20,000.
Mean unit price
Six presentations [23·1%] had a mean unit price below
$100.00 and nine drugs [34·6%] had a mean unit price be-
tween $100·00 and $500·00. Eight drugs [30·7%] had a mean
unit price of over $1000.00, of which, one [cabazitaxel] had
a mean unit price of over $5000·00 [$11,832·9/vial]. Overall,
Taiwan had the lowest mean unit prices[$492·61] and
Oman the highest [$2355·6]. So Overall, Taiwan had the
lowest mean unit prices for all presentations.
The average unit prices by country income category
were as follows: LMICs $814.07, HMICs $1150·63, HICs:
$1148·19. Using PPP-adjusted mean unit prices, the
three most expensive presentations were found to be
cabazitaxel [$11,832·93], trastuzumab 440 mg [$4779·35],
and panitumumab [$4146·99]. The three cheapest oncol-
ogy drugs were lapatinib ditosylate [$40·08], pazopanib
disodium heptahydrate [$52·20], and imatinib [$56·92].
The high/low ratio
The high/ low ratio data included in Table 3 allowed us to
look at the price deviation between countries. The high/
low unit price ratio was less than 3 for fourteen drugs
[53·80% of the 26 total included products], between 3 and
6 for eight drugs [30·77%] and more than 6 for four drugs
[15·38%]. The smallest high/low ratio was 1·07, which
belonged to sunitinib malate 25 mg, and the largest high/
low ratio belonged to Interferon alpha-2B [13·68] [Table 3].
The frequency of unit prices ranked in quartiles
Box plots have been constructed based on the unit $
price of the included drugs. The boxplot for low and
high price cancer medicines have been presented separ-
ately in Fig. 2a and b to ensure that the differences are
easy to discern. The box plot displays the inter-quartile
range [IQR] as calculated by Microsoft Excel; the bottom
and top of the box are the 25th and 75th percentiles [the
1st and the 3rd quartiles, respectively], and the band in
the middle of the box is the median. The extended lines
describe the bottom and top whiskers.
Drug prices varied significantly across the included
countries. Figure 3 represents the frequency of unit prices,
as of February 2016, ranked in quartiles [Note: quartile 1
and 4 are not inclusive of the minimum and maximum
values; these values have been categorized and represented
Table 2 Background information about drugs included in the analysisa (Continued)
Generic drug
name
Product name FDA approved indications Selected presentation Country coverage Unit price is
price of:# Missing data
Pemetrexed
Disodium
Heptahydrate
Malignant pleural mesothelioma One vial containing 20 mg/ml
solution for injection.
Sorafenib Nexavar (Bayer
Schering)
Liver cancer
Kidney cancer
Thyroid cancer
60 film-coated tablets 200 mg. 5 THA, MYS, OMN,
BHR,LBN
1 film coated
Tab
Sunitinib
malate
SUTENT (Pfizer) Kidney cancer
Gastointestinal stromal tumour
Pancreatic Neuroendocrine
tumours
28 capsules 12.5 mg 7 OMN, LBN, BHR 1 Cap
28 capsules 25 mg 4 THA, LBN, MYS,
OMN, BHR, TWN,
1 Cap
28 capsules 50 mg 6 THA, LBN, MYS,
OMN,
1 Cap
Trastuzumab Herceptin
(Roche)
Her2 over expressing breast
cancer
Her2 over expressive Gastric
or Gastroesophageal junction
Adenocarcinoma
One vial containing 440 mg
powder for concentrate for
solution for infusion
4 THA, LBN, MYS,
SAU,OMN, BHR
1 Vial
One vial containing 150 mg
powder for concentrate for
solution for infusion
4 ARE, EGYP, PAK, LBN,
MYS, TWN,
1 Vial
Zolendronic
acid
ZOLDIC Multiple Myeloma One vial containing 4 mg/5 ml
concentrate for solution for
infusion
4 ARE, LBN, MYS, OMN,
BHR, TWN
1 Vial
aThe National Cancer Institute. A to Z List of Cancer Drugs. USA: The National Institutes of Health U.S. Department of Health and Human Services, 2015
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separately using unique colours of their own]. Thailand
and Taiwan had prices at the lower end, prices in Lebanon
mainly fell in the first quartile, while prices in the
United Arab Emirates and Bahrain fell in the second
and third quartiles. Prices in Oman and Saudi Arabia
were at the upper end [Fig. 3]. Prices in Oman were
ranked the most expensive for eight presentations
(Additional file 1: Table S3).
Prices in high income countries are at the upper end,
and are ranked as the maximum for 13 of the included
presentations, while prices in low middle income coun-
tries were ranked the most expensive for six presenta-
tions only [Fig. 4].
Discussion
The aim of the present study was to survey and compare
retail prices of anti-cancer drugs between high, middle
and low-income countries in the South-East Asia, Western
Pacific and Eastern Mediterranean regions. In the absence
of a systematic pricing system, pharmaceutical companies
determine the drug price according to what the society can
afford, as people are ready to face a heavy financial burden
when it comes to treating fatal diseases [13]. In some devel-
oped countries, price regulation measures such as external
reference pricing or international reference pricing have
been widely used by policymakers to restrain drug costs.
External reference pricing is defined by the WHO as: “The
practice of using the price[s] of a medicine in one or several
countries in order to derive a benchmark or reference price
for the purposes of setting or negotiating the price of the
product in a given country” [14].
A list of 2010 cancer drug prices, has been published
by the Management Sciences for Health based on the
WHO’s 17th edition of the Essential Medicines List [15].
This is the only procurement tool available to the pricing
authorities in LMICs, however, more support is needed
such as an updated WHO essential medicine list section
on oncology drugs along with cross-country pricing in-
formation and procurement guidance. Although the
Western Pacific Region office of the WHO has devel-
oped a Price Information Exchange that provides com-
parative information on procurement prices for selected
medicines across the Western Pacific region [15], it has
faced many challenges such as lack of cooperation from
Fig. 2 a Boxplots of incuded cancer drugs with mean USD unit price between 1 and 1000. b Boxplots of included cancer drugs with mean USD
unit price between 1,000 and 20,0000
Fig. 1 a Included cancer drugs with unit prices between 1-1000 USD stratified by country. b Included cancer drugs with unit prices between
1000-20,000 USD stratified by country
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member countries. This is why we have attempted to
undertake our own cross-country price comparison [13].
Purchasing power parity conversion rates were used
instead of exchanges rate in this review. Exchange rates
determine the producers’ actual profit from foreign sales
in terms of domestic currencies [16], and can be used
when performing pharmaco-economic studies within a
country since the expected exchange rate fluctuations
would affect all drugs sourced from the same country,
uniformly. In cross-country comparisons, however, to
overcome the effect of large fluctuations in exchange rates,
the PPP is used as an alternative sensitivity analysis [17].
Purchasing power parity conversions are also argued to be
more apt for comparisons at final consumer level [16].
Our review showed extreme variation between drug
prices across countries; the high/low ratios were as high
as 13·68 [PPP-adjusted]. While patents can explain the
price differences between drugs, they are not responsible
for the price differences observed for the same medicine.
Greater transparency of price information among
countries may assist with in-country negotiations be-
tween purchasers and suppliers. Information on the
availability of cheaper medicines in neighbouring coun-
tries has the potential to encourage policy and manager-
ial decisions at national levels in an effort to reduce
prices [15]. Economic evidence on the impact of external
reference pricing is scarce. Only a few studies have expli-
citly analysed the impact of external price referencing on
medicine prices. Stargardt et al., [18] using an analytic
model to simulate the effect of a price reduction in
Germany demonstrated that every 1 EURO reduction in
price in Germany would lead to a reduction of EURO
0.15 to EURO 0.36 in 15 European countries that use
external reference pricing. Similar results were reported
Fig. 4 Frequency of PPP-adjusted unit prices ranked in quartiles for each income group
Fig. 3 Frequency of PPP-adusted unit prices ranked in quartiles for each country
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by Windmeijer et al. [19] who investigated the result of
external reference pricing implementation on prices in
Netherlands. Our study can hence be used by officials to
improve access to cancer treatment [13].
Limitations
Cross-country comparison of pharmaceutical prices is
challenging because of the differing level of sales, fre-
quent changes in exchange rates and the differences in
the pharmaceutical presentations such as strength, pack
size, dose and dosage form. Of the 57 countries in the
South-East Asia, Eastern Mediterranean and Western
Pacific regions (excluding Australia and New Zealand),
we only managed to find reliable pricing information for
ten countries only due to: [i] under-developed/incom-
plete/not-user-friendly websites of official pricing/heath
authorities; [ii] use of languages other than English in of-
ficial websites; [iii] lack of public access to official drug
prices; and [iv] absence of an official institution to
summarize/compare prices across Asia. However, we
managed to include representative countries from differ-
ent ranges of GNI per capita. The other key limitations
of this study are as follows: Firstly, the prices may not
reflect the true cost of medications because the retrieved
data are the official prices as published by the pricing
authorities without consideration of [usually confiden-
tial] discounts and rebates. Secondly, this study used re-
tail prices, which include add-ons such as taxes and
distribution fees. Understanding of the amount and
sources of add-ons would identify potential targets for
price reduction. Unfortunately, data on add-ons was lim-
ited and hence we were unable to estimate them.
Thirdly, the use of PPP calculations for price comparison
required the assumptions that the value of goods and
services are homogeneous across countries and that
international shipment of goods takes place instantan-
eously, and with no cost. Unit prices were used to com-
pare results in this study, when interpreting the results
of this study, it should be kept in mind that one unit
may refer to the daily dose of a tablet, or monthly vial
for injection or a weight based two weekly injections.
Future studies should use the data provided in this study
and perform a price comparison using monthly dose or
total treatment cost, as a unit for measurement and
comparison. Finally, pricing revisions are done at irregu-
lar intervals and the price lists may not be updated im-
mediately. However, most recently available prices were
used for calculations.
Conclusion
The significant price differences among Asian countries
is very evident. Taiwan had the lowest mean unit price
[$492·61] and Oman the highest [$2355·60]. Significant
variation between drug prices across countries with the
highest high/low ratio was seen for Interferon alpha-2B:
13.68. Cabazitaxel was ranked the most expensive drug
in our sample with a mean unit price of $17,304·95.
These discrepancies indicate that greater price transpar-
ency is required. Our goal was to compare cancer drug
prices and investigate whether the prices are significantly
different among countries. Significant differences were
found and reported accordingly, however, what this price
differences mean in terms of access to cancer medica-
tions, government spending, and patient adherence, re-
quires a much more in-depth analysis of each country’s
respective health care system, which was beyond the
scope of this paper.
Our results can be used to help policy makers to com-
pare the price of anti-cancer agents in their country with
that in neighbouring countries to decide if further policy
measures related to drug prices are required.
Key issues
 Anti-cancer drug prices are highly variable in the
South-East Asian, Western Pacific and Eastern
Mediterranean regions.
 There is an association between price of anticancer
drugs and income category of the country.
 Almost one in three drugs assessed in this study had
a mean unit price of more than US$ 1000.
 There is a need to review pricing policy in order to
improve accessibility and affordability of cancer
drugs in the selected countries.
Additional file
Additional file 1: Table S1. The purchasing power parity conversion
rates used. Table S2. The respective GNI per capita and country
classifications. Table S3. (XLSX 72 kb)
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